Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
741-760 of 1,743 trials

Crohn's Disease: Vedolizumab with Upadacitinib

We are studying whether a combination of vedolizumab and upadacitinib helps improve symptoms in adults with moderately to severely active Crohn's disease compared to vedolizumab alone.

Crohn's Disease>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Frontotemporal Dementia: AVB-101 Treatment Study

We are testing a new treatment called AVB-101 for individuals with frontotemporal dementia due to specific genetic mutations. The study aims to assess its safety and early effects on symptoms.

Frontotemporal Dementia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementNeurology

ILUVIEN® Eye Implant for Children with Uveitis

We are studying the safety and effectiveness of the ILUVIEN® eye implant in children aged 6 to under 18 with recurrent non-infectious uveitis. This research aims to understand how well the implant works and any possible side effects.

Posterior Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementOphthalmologyPediatrics

Soft-Tissue Sarcoma: Intensified Chemotherapy Study

We are investigating whether adding extra chemotherapy cycles helps high-risk patients with resectable soft-tissue sarcomas have better outcomes after surgery. This study compares the effects of different chemotherapy regimens on survival rates.

Resectable Non-Metastatic Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Advanced Solid Tumors: Atezolizumab with EIK10001 and Radiation

We are studying a new treatment combining atezolizumab, EIK10001, and radiation for patients with advanced solid tumors like pancreatic cancer and triple-negative breast cancer. This trial aims to evaluate how well this combination works in controlling cancer.

Metastatic Solid Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Advanced Sarcomas: Pembrolizumab and Cabozantinib Study

We are investigating the effects of a combination of pembrolizumab and cabozantinib in patients with advanced sarcomas. The goal is to see if this treatment can help prevent disease progression and improve overall outcomes.

Advanced Metastatic Sarcomas>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Sarcoma: Bintrafusp Alfa and Doxorubicin

We are studying a new treatment combining Bintrafusp alfa with doxorubicin for patients with advanced sarcoma. The goal is to see if this combination improves tumor response and safety compared to standard treatments.

Soft-Tissue Sarcomas>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Colorectal Cancer: RO7198457 Treatment Study

We are comparing a new treatment called RO7198457 to watchful waiting in patients with high-risk, resected Stage II and Stage III colorectal cancer. The goal is to see if the new treatment can help prevent cancer recurrence better than simply monitoring.

Stage II/Stage III Rectal Cancer or Stage II (High Risk)/Stage III Colon Cancer>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncology

LB-208 for Relapsed Solid Tumors and Lymphoma

We are testing a new medication for adults with solid tumors or lymphoma that have not responded to other treatments. This study aims to evaluate its safety and potential effectiveness.

LymphomaSolid Tumor>2 yearsSafety phase (I)Oncology

Geographic Atrophy: Pozelimab and Cemdisiran Study

We are investigating whether a new treatment combining pozelimab with cemdisiran helps slow the progression of geographic atrophy in adults. This study aims to understand its effects on vision and safety compared to cemdisiran alone.

Geographic Atrophy from Age-Related Macular Degeneration>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineOphthalmology

Colorectal Cancer: Intermittent vs. Continuous Treatment with Panitumumab

We are studying whether an intermittent treatment of Panitumumab with FOLFIRI is as effective as continuous treatment for patients with metastatic left-sided colorectal cancer. The trial also aims to assess safety and quality of life for participants.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Tick-Borne Encephalitis: Novel Cytokine Release Assay

We are studying a new test to measure immune responses to Tick-Borne Encephalitis in healthy and immunosuppressed individuals. This research aims to improve understanding of how well the immune system responds to the virus and vaccination.

Tick-borne Encephalitis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesAllergologyInfectious Diseases

MEPENDAX: Axitinib and Etoposide for Pediatric Brain Tumors

We are studying a new treatment combining axitinib and oral etoposide for children and young adults with relapsing medulloblastoma or ependymoma. The goal is to find the safest dose and see if it helps improve survival.

MedulloblastomaEpendymoma>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesNeurologyOncologyPediatrics

Crohn's Disease: Upadacitinib for Children

We are studying the effects of Upadacitinib in children with active Crohn's disease who haven't had success with other treatments. The goal is to see if it helps them achieve better health outcomes.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Peyronie's Disease: Study of Bacterial Collagenase

We are testing a new bacterial collagenase injection for men with Peyronie's Disease to see if it improves penile curvature and reduces discomfort. The study will assess both safety and effectiveness of this treatment.

Peyronie's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesUrology

Extensive-Stage Small Cell Lung Cancer: I-DXd with Atezolizumab

We are studying a new treatment combining I-DXd and atezolizumab, with or without carboplatin, for patients with extensive-stage small cell lung cancer. The trial aims to assess safety and effectiveness as a first-line treatment.

Extensive-stage Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Recurrent or Metastatic Solid Tumors: I-DXd Treatment Study

We are testing a new treatment called I-DXd for patients with recurrent or metastatic solid tumors. The study aims to see how well it works and how safe it is for participants.

Recurrent or Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Solid Tumors: ANV600 and Pembrolizumab Study

We are testing a new treatment, ANV600, alone and with pembrolizumab for people with advanced solid tumors. The goal is to evaluate safety and how well it may help fight cancer.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Peripheral T Cell Lymphoma: LIS1 Antibody Study

We are testing a new antibody treatment for patients with relapsed or refractory peripheral T cell lymphoma. The study aims to evaluate its safety and effectiveness in fighting this type of cancer.

Peripheral T-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

ADP-TILIL7: New Treatment Study

We are exploring a new treatment for patients with specific health conditions. Our goal is to understand its effects and potential benefits compared to existing therapies.

Advanced Melanoma>2 yearsSafety phase (I)Oncology